Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Early Detection of Cancer | 30 | 2025 | 513 | 4.520 |
Why?
|
| Colorectal Neoplasms | 27 | 2025 | 616 | 4.480 |
Why?
|
| Colonoscopy | 14 | 2025 | 253 | 2.130 |
Why?
|
| Occult Blood | 15 | 2025 | 154 | 1.430 |
Why?
|
| Mass Screening | 14 | 2025 | 667 | 1.070 |
Why?
|
| Aged | 40 | 2025 | 6150 | 0.890 |
Why?
|
| Patient Compliance | 4 | 2020 | 299 | 0.860 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 387 | 0.850 |
Why?
|
| Public Health | 3 | 2020 | 81 | 0.850 |
Why?
|
| Humans | 57 | 2025 | 17707 | 0.820 |
Why?
|
| Safety-net Providers | 6 | 2020 | 51 | 0.810 |
Why?
|
| Middle Aged | 39 | 2025 | 7976 | 0.810 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 139 | 0.790 |
Why?
|
| Electronic Health Records | 9 | 2020 | 694 | 0.740 |
Why?
|
| Medicaid | 7 | 2025 | 188 | 0.700 |
Why?
|
| Postal Service | 9 | 2025 | 73 | 0.630 |
Why?
|
| Patient Navigation | 3 | 2025 | 15 | 0.630 |
Why?
|
| Female | 42 | 2025 | 12729 | 0.630 |
Why?
|
| Male | 41 | 2025 | 10094 | 0.620 |
Why?
|
| Patient Selection | 3 | 2024 | 190 | 0.590 |
Why?
|
| Community Health Centers | 4 | 2020 | 65 | 0.570 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2016 | 181 | 0.500 |
Why?
|
| Oregon | 8 | 2025 | 187 | 0.450 |
Why?
|
| Clostridium difficile | 4 | 2016 | 22 | 0.440 |
Why?
|
| Feces | 7 | 2020 | 80 | 0.430 |
Why?
|
| Qualitative Research | 5 | 2024 | 257 | 0.410 |
Why?
|
| Colonic Neoplasms | 3 | 2020 | 158 | 0.390 |
Why?
|
| Risk Assessment | 6 | 2019 | 1106 | 0.370 |
Why?
|
| Glomerular Filtration Rate | 7 | 2016 | 154 | 0.370 |
Why?
|
| Case Management | 1 | 2010 | 32 | 0.340 |
Why?
|
| Diffusion of Innovation | 1 | 2010 | 37 | 0.340 |
Why?
|
| Retrospective Studies | 16 | 2020 | 2471 | 0.340 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 46 | 0.330 |
Why?
|
| Kidney Diseases | 4 | 2010 | 53 | 0.330 |
Why?
|
| Northwestern United States | 6 | 2016 | 53 | 0.320 |
Why?
|
| Heart Failure | 2 | 2012 | 398 | 0.300 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 280 | 0.300 |
Why?
|
| Adult | 16 | 2024 | 7658 | 0.300 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 125 | 0.300 |
Why?
|
| Medicare | 5 | 2022 | 199 | 0.300 |
Why?
|
| Aged, 80 and over | 15 | 2016 | 1927 | 0.290 |
Why?
|
| United States | 14 | 2025 | 3914 | 0.290 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 211 | 0.290 |
Why?
|
| Rural Population | 2 | 2025 | 52 | 0.290 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 67 | 0.270 |
Why?
|
| Primary Health Care | 5 | 2024 | 756 | 0.260 |
Why?
|
| Research Design | 3 | 2019 | 372 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 3 | 2012 | 151 | 0.250 |
Why?
|
| Hospitalization | 2 | 2010 | 805 | 0.250 |
Why?
|
| Analgesics, Opioid | 3 | 2013 | 243 | 0.240 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 355 | 0.240 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 710 | 0.240 |
Why?
|
| Hispanic Americans | 4 | 2016 | 397 | 0.240 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 1218 | 0.240 |
Why?
|
| Renal Replacement Therapy | 3 | 2016 | 9 | 0.240 |
Why?
|
| Reminder Systems | 3 | 2023 | 80 | 0.240 |
Why?
|
| Data Accuracy | 1 | 2024 | 27 | 0.230 |
Why?
|
| Information Dissemination | 1 | 2024 | 50 | 0.230 |
Why?
|
| Specimen Handling | 1 | 2024 | 20 | 0.230 |
Why?
|
| Prognosis | 7 | 2020 | 613 | 0.220 |
Why?
|
| Clostridium Infections | 2 | 2016 | 11 | 0.220 |
Why?
|
| Rural Health Services | 1 | 2024 | 13 | 0.220 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2014 | 13 | 0.220 |
Why?
|
| Blood Pressure | 3 | 2016 | 300 | 0.220 |
Why?
|
| Forecasting | 2 | 2020 | 74 | 0.200 |
Why?
|
| Back Pain | 2 | 2013 | 33 | 0.200 |
Why?
|
| Anemia | 2 | 2012 | 34 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2020 | 28 | 0.170 |
Why?
|
| Hemoglobins | 3 | 2016 | 39 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 203 | 0.150 |
Why?
|
| Program Evaluation | 3 | 2020 | 222 | 0.140 |
Why?
|
| Neoplasms | 1 | 2022 | 442 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2016 | 177 | 0.140 |
Why?
|
| Models, Biological | 1 | 2016 | 30 | 0.140 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2017 | 61 | 0.130 |
Why?
|
| Interviews as Topic | 5 | 2017 | 301 | 0.130 |
Why?
|
| Health Maintenance Organizations | 2 | 2010 | 414 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1322 | 0.130 |
Why?
|
| Risk Management | 1 | 2016 | 3 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.130 |
Why?
|
| Cross Infection | 1 | 2016 | 27 | 0.130 |
Why?
|
| Cohort Studies | 8 | 2015 | 2589 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2020 | 189 | 0.120 |
Why?
|
| Risk | 2 | 2014 | 517 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 381 | 0.120 |
Why?
|
| Population Surveillance | 2 | 2014 | 265 | 0.120 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 42 | 0.120 |
Why?
|
| Drug Utilization | 2 | 2012 | 124 | 0.120 |
Why?
|
| Time Factors | 4 | 2019 | 1095 | 0.110 |
Why?
|
| Individuality | 1 | 2014 | 2 | 0.110 |
Why?
|
| Logistic Models | 3 | 2013 | 918 | 0.110 |
Why?
|
| Sodium | 1 | 2014 | 12 | 0.110 |
Why?
|
| Age Factors | 5 | 2016 | 918 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 19 | 0.110 |
Why?
|
| Referral and Consultation | 3 | 2021 | 165 | 0.110 |
Why?
|
| Cost Savings | 2 | 2011 | 22 | 0.110 |
Why?
|
| Health Literacy | 1 | 2014 | 40 | 0.110 |
Why?
|
| Perception | 1 | 2013 | 57 | 0.110 |
Why?
|
| Testosterone | 1 | 2013 | 23 | 0.110 |
Why?
|
| Erectile Dysfunction | 1 | 2013 | 24 | 0.110 |
Why?
|
| Incidence | 5 | 2020 | 1269 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2014 | 112 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2014 | 241 | 0.100 |
Why?
|
| Aging | 1 | 2014 | 163 | 0.100 |
Why?
|
| Research Report | 1 | 2012 | 23 | 0.100 |
Why?
|
| Benchmarking | 1 | 2012 | 40 | 0.100 |
Why?
|
| Low Back Pain | 1 | 2012 | 53 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2014 | 151 | 0.100 |
Why?
|
| Proteinuria | 1 | 2012 | 26 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 71 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2012 | 70 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2022 | 1254 | 0.090 |
Why?
|
| Laboratories | 1 | 2011 | 18 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 40 | 0.090 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 17 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 142 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2012 | 222 | 0.090 |
Why?
|
| Telephone | 2 | 2023 | 161 | 0.090 |
Why?
|
| Systole | 3 | 2016 | 22 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 243 | 0.090 |
Why?
|
| Lisinopril | 1 | 2010 | 5 | 0.090 |
Why?
|
| Washington | 3 | 2019 | 382 | 0.080 |
Why?
|
| Young Adult | 5 | 2016 | 2450 | 0.080 |
Why?
|
| Hyperkalemia | 1 | 2010 | 16 | 0.080 |
Why?
|
| Phosphorus | 1 | 2009 | 6 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 86 | 0.080 |
Why?
|
| Health Services Research | 1 | 2010 | 213 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2011 | 324 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 327 | 0.080 |
Why?
|
| Colorado | 3 | 2014 | 164 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 448 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2010 | 248 | 0.070 |
Why?
|
| Comorbidity | 3 | 2014 | 590 | 0.070 |
Why?
|
| Chronic Disease | 4 | 2010 | 416 | 0.070 |
Why?
|
| Efficiency, Organizational | 1 | 2007 | 29 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2007 | 57 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 78 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2007 | 95 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 131 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 215 | 0.060 |
Why?
|
| Communication | 2 | 2019 | 191 | 0.060 |
Why?
|
| Internet | 1 | 2007 | 229 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 129 | 0.050 |
Why?
|
| Community-Institutional Relations | 1 | 2024 | 42 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 596 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 639 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 2 | 2012 | 18 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2012 | 237 | 0.050 |
Why?
|
| Drug Prescriptions | 2 | 2013 | 151 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 626 | 0.050 |
Why?
|
| Health Services | 2 | 2012 | 114 | 0.050 |
Why?
|
| California | 2 | 2019 | 2327 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 101 | 0.050 |
Why?
|
| Health Behavior | 2 | 2014 | 360 | 0.040 |
Why?
|
| Morbidity | 1 | 2021 | 59 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2012 | 670 | 0.040 |
Why?
|
| Risk Factors | 3 | 2014 | 3367 | 0.040 |
Why?
|
| Biomarkers | 2 | 2012 | 312 | 0.040 |
Why?
|
| Immunochemistry | 1 | 2020 | 18 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 3671 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 68 | 0.040 |
Why?
|
| Mental Disorders | 2 | 2012 | 276 | 0.040 |
Why?
|
| Text Messaging | 1 | 2019 | 29 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 521 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 882 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 132 | 0.040 |
Why?
|
| Organizational Culture | 1 | 2017 | 16 | 0.040 |
Why?
|
| Awareness | 1 | 2017 | 17 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2017 | 11 | 0.040 |
Why?
|
| Leadership | 1 | 2017 | 34 | 0.030 |
Why?
|
| Health Promotion | 1 | 2019 | 280 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1117 | 0.030 |
Why?
|
| Albuminuria | 1 | 2016 | 38 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 1287 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2016 | 113 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 15 | 0.030 |
Why?
|
| British Columbia | 1 | 2015 | 3 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 71 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 159 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 181 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 1322 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 45 | 0.030 |
Why?
|
| Comprehension | 1 | 2014 | 17 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 93 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 65 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 44 | 0.030 |
Why?
|
| Financing, Government | 1 | 2014 | 27 | 0.030 |
Why?
|
| Language | 1 | 2014 | 52 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 371 | 0.030 |
Why?
|
| Vardenafil Dihydrochloride | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tadalafil | 1 | 2013 | 2 | 0.030 |
Why?
|
| Carbolines | 1 | 2013 | 2 | 0.030 |
Why?
|
| Sulfones | 1 | 2013 | 2 | 0.030 |
Why?
|
| Triazines | 1 | 2013 | 2 | 0.030 |
Why?
|
| Urological Agents | 1 | 2013 | 2 | 0.030 |
Why?
|
| Purines | 1 | 2013 | 3 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 4 | 0.030 |
Why?
|
| Sildenafil Citrate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Piperazines | 1 | 2013 | 9 | 0.030 |
Why?
|
| Androgens | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 22 | 0.030 |
Why?
|
| Demography | 1 | 2012 | 100 | 0.030 |
Why?
|
| Metronidazole | 1 | 2012 | 4 | 0.020 |
Why?
|
| Vancomycin | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2012 | 94 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 34 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 77 | 0.020 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 102 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 348 | 0.020 |
Why?
|
| Health Records, Personal | 1 | 2011 | 13 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 107 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2012 | 57 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 175 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 48 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 717 | 0.020 |
Why?
|
| Patient Safety | 1 | 2011 | 38 | 0.020 |
Why?
|
| Decision Making | 1 | 2012 | 182 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 304 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2012 | 227 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 266 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 137 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 483 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 140 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 314 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 262 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2011 | 313 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2009 | 2 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 332 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 216 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1199 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 504 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1417 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 50 | 0.020 |
Why?
|
| Bone Density | 1 | 2007 | 97 | 0.020 |
Why?
|
| Organizations, Nonprofit | 1 | 2007 | 11 | 0.020 |
Why?
|
| Child | 1 | 2012 | 2481 | 0.020 |
Why?
|
Concepts
(236)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->